Google
Apple
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
NOVARTIS AG |
Market Closed -
Other stock markets
|
|
5-day change | 1st Jan Change | |
| 84.25 CHF | -0.75% | -1.02% | +0.79% | |
| 12:09pm | Daiichi Sankyo Subsidiary, Plexxikon, Wins Patent Lawsuit; Novartis to Pay $182 Million Settlement | MT |
| 12:09pm | European Midday Briefing : Disappointing Data Weigh on Sentiment | DJ |
| Sales 2023 * | 46.23B 40.48B | Sales 2024 * | 47.51B 41.6B | Capitalization | 200B 175B |
|---|---|---|---|---|---|
| Net income 2023 * | 9.82B 8.6B | Net income 2024 * | 10.29B 9.01B | EV / Sales 2023 * | 4,59x |
| Net Debt 2023 * | 12.84B 11.25B | Net Debt 2024 * | 12.39B 10.85B | EV / Sales 2024 * | 4,46x |
| P/E ratio 2023 * | 18,8x | P/E ratio 2024 * | 17,9x | Employees | 101,703 |
| Yield 2023 * | 3,64% | Yield 2024 * | 3,80% | Free-Float | 86.85% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | -0.70% | ||
| 1 week | -1.02% | ||
| Current month | -1.02% | ||
| 1 month | +0.08% | ||
| 3 months | -4.94% | ||
| 6 months | -5.87% | ||
| Current year | +0.79% |
1 week
83.90
86.41
1 month
83.0986.79
Current year
73.7494.77
1 year
73.7494.77
3 years
72.8494.77
5 years
65.0996.38
10 years
65.09103.20
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 47 | 2004 | |
| Director of Finance/CFO | 58 | 2002 | |
Shreeram Aradhye
CTO | Chief Tech/Sci/R&D Officer | 61 | 2022 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Bill Winters
BRD | Director/Board Member | 61 | 2012 |
Simon Moroney
BRD | Director/Board Member | 64 | 2020 |
| Chairman | 67 | 2012 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 16.67% | 2,109 M€ | +2.16% | ||
| 16.47% | 2,038 M€ | +2.19% | - | |
| 15.31% | 9 M€ | 0.00% | - | |
| 15.06% | 1,165 M€ | -.--% | ||
| 15.06% | 455 M€ | +3.03% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 23-12-07 | 84.25 | -0.75% | 2 474 198 |
| 23-12-06 | 84.89 | -0.20% | 3,666,617 |
| 23-12-05 | 85.06 | -1.25% | 3,492,673 |
| 23-12-04 | 86.14 | +0.89% | 2,761,427 |
| 23-12-01 | 85.38 | +0.31% | 2,277,071 |
Delayed Quote Swiss Exchange, December 07, 2023 at 11:30 am EST
More quotes
Novartis AG is one of the world's leaders in the design, manufacturing, and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- pharmaceutical products (81.7%): used to treat cardiovascular, respiratory, and dermatological diseases, gastrointestinal disorders, cancers, central nervous system disorders, hormone imbalances, etc.;
- generic drugs (18.3%; Sandoz).
Net sales are distributed geographically as follows: Europe (36.5%), the United States (34.9%), Asia/Africa/Australasia (20.9%), Canada and Latin America (7.7%).
Sector
Pharmaceuticals
Calendar
2024-01-07
- JPMorgan Healthcare Conference
Trading Rating :
Investor Rating :
ESG Refinitiv :
B-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
20
Last Close Price
97.09USD
Average target price
105.75USD
Spread / Average Target
+8.92%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +0.79% | 200 B $ | |
| +59.98% | 530 B $ | |
| +42.05% | 438 B $ | |
| -11.74% | 377 B $ | |
| -5.69% | 268 B $ | |
| -8.46% | 258 B $ | |
| -14.13% | 230 B $ | |
| -9.98% | 198 B $ | |
| -43.93% | 163 B $ | |
| +3.69% | 144 B $ |
